Literature DB >> 23791972

Mesenchymal stem cells transplantation ameliorates glomerular injury in streptozotocin-induced diabetic nephropathy in rats via inhibiting macrophage infiltration.

Sha-Sha Lv1, Gang Liu, Jian-Ping Wang, Wei-Wei Wang, Jing Cheng, Ai-Li Sun, Hai-Ying Liu, Hui-Bin Nie, Mo-Ran Su, Guang-Ju Guan.   

Abstract

Mesenchymal stem cells (MSCs) treatment has been shown to be effective in diabetic nephropathy (DN). However, the mechanisms involved in the renoprotective effects of MSCs have not been clearly demonstrated. Especially, there was no study on the relationship of MSCs and macrophages in diabetic kidney. To explore the effect of MSCs on macrophages in DN, streptozotocin-induced diabetes animals received no treatment or treatment with MSCs (2×10(6), via tail vein) for two continuous weeks. Eight weeks after treatment, physical, biochemical and morphological parameters were measured. Immunohistochemistry for fibronectin (FN), CollagenI, ED-1, monocyte chemoattractant protein-1 (MCP-1) was performed. Expressions of pro-inflammatory cytokines and hepatocyte growth factor (HGF) at gene level and protein level were determined by real-time reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. Blood glucose, urinary albumin excretion, creatinine clearance were significantly reduced after MSCs treatment. The glomerulosclerosis as revealed by periodic acid Schiff stain and expression of FN and CollagenI was also dramatically attenuated. Most importantly, the expression of MCP-1 and the number of infiltrated macrophages in kidney were effectively suppressed by MSCs treatment. The expression of HGF in MSCs group was up-regulated. Meanwhile, the expressions of IL-1β, IL-6 and TNFα were significantly down-regulated by MSCs treatment. Our study suggest that MSCs treatment ameliorates DN via inhibition of MCP-1 expression by secreting HGF, thus reducing macrophages infiltration, down-regulating IL-1β, IL-6, TNFα expression in renal tissue in diabetic rats.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bone marrow mesenchymal stem cells; Diabetic rats; Inflammation; Macrophages; Nephropathy

Mesh:

Substances:

Year:  2013        PMID: 23791972     DOI: 10.1016/j.intimp.2013.05.031

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  31 in total

Review 1.  Administration of mesenchymal stem cells in diabetic kidney disease: mechanisms, signaling pathways, and preclinical evidence.

Authors:  Yuexin Zhu; Manyu Luo; Xue Bai; Yan Lou; Ping Nie; Shan Jiang; Jicui Li; Bing Li; Ping Luo
Journal:  Mol Cell Biochem       Date:  2022-04-25       Impact factor: 3.396

Review 2.  The future of diabetic kidney disease management: what to expect from the experimental studies?

Authors:  Federica Barutta; Stefania Bellini; Beatrice Corbetta; Marilena Durazzo; Gabriella Gruden
Journal:  J Nephrol       Date:  2020-03-27       Impact factor: 3.902

Review 3.  The Promise of Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease.

Authors:  Tomás P Griffin; William Patrick Martin; Nahidul Islam; Timothy O'Brien; Matthew D Griffin
Journal:  Curr Diab Rep       Date:  2016-05       Impact factor: 4.810

4.  Diabetic Kidney Disease Alters the Transcriptome and Function of Human Adipose-Derived Mesenchymal Stromal Cells but Maintains Immunomodulatory and Paracrine Activities Important for Renal Repair.

Authors:  LaTonya J Hickson; Alfonso Eirin; Sabena M Conley; Timucin Taner; Xiaohui Bian; Ahmed Saad; Sandra M Herrmann; Ramila A Mehta; Travis J McKenzie; Todd A Kellogg; James L Kirkland; Tamar Tchkonia; Ishran M Saadiq; Hui Tang; Kyra L Jordan; Xiangyang Zhu; Mathew D Griffin; Andrew D Rule; Andre J van Wijnen; Stephen C Textor; Lilach O Lerman
Journal:  Diabetes       Date:  2021-04-15       Impact factor: 9.337

Review 5.  Cell-based therapies for experimental chronic kidney disease: a systematic review and meta-analysis.

Authors:  Diana A Papazova; Nynke R Oosterhuis; Hendrik Gremmels; Arianne van Koppen; Jaap A Joles; Marianne C Verhaar
Journal:  Dis Model Mech       Date:  2015-01-29       Impact factor: 5.758

6.  Icariside II ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats.

Authors:  Wenjie Tian; Hongen Lei; Ruili Guan; Yongde Xu; Huixi Li; Lin Wang; Bicheng Yang; Zhezhu Gao; Zhongcheng Xin
Journal:  Drug Des Devel Ther       Date:  2015-09-07       Impact factor: 4.162

Review 7.  Trophic Factors from Tissue Stem Cells for Renal Regeneration.

Authors:  Kenji Tsuji; Shinji Kitamura
Journal:  Stem Cells Int       Date:  2015-05-18       Impact factor: 5.443

Review 8.  Progress toward the Clinical Application of Mesenchymal Stromal Cells and Other Disease-Modulating Regenerative Therapies: Examples from the Field of Nephrology.

Authors:  LaTonya J Hickson; Sandra M Herrmann; Bairbre A McNicholas; Matthew D Griffin
Journal:  Kidney360       Date:  2021-03

Review 9.  The Multi-Therapeutic Role of MSCs in Diabetic Nephropathy.

Authors:  Yi Wang; Su-Kang Shan; Bei Guo; Fuxingzi Li; Ming-Hui Zheng; Li-Min Lei; Qiu-Shuang Xu; Muhammad Hasnain Ehsan Ullah; Feng Xu; Xiao Lin; Ling-Qing Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-07       Impact factor: 5.555

10.  Under the right conditions: protecting podocytes from diabetes-induced damage.

Authors:  Imran H A Ali; Derek P Brazil
Journal:  Stem Cell Res Ther       Date:  2013       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.